The fourth red flag concerns a new obligation the recommendations impose on companies and sponsors submitting to the HTA process and the peculiar absence of any focus on a critical issue considered an Albanese Government priority. …
The HTA Review report - 'Red Flag' number four of five
September 18, 2024 Latest NewsBioPharmaCommentNews of the Day
Latest Video
New Stories
-
Medicines Australia announces appointment of communications director
April 28, 2025 - - Latest News -
New survey confirms significant interest in accessing weight loss therapies
April 28, 2025 - - Latest News -
Recce Pharmaceuticals enters research and development agreement with US defence
April 28, 2025 - - Australian Biotech -
Radiopharm Theranostics doses first patient in US Phase 2b imaging study of brain metastasis
April 28, 2025 - - Australian Biotech -
Dimerix says FDA confirms proteinuria as acceptable endpoint for DMX-200 Phase 3 trial
April 28, 2025 - - Australian Biotech -
Stakeholders welcome the PBS listing of AbbVie's blood cancer therapy
April 28, 2025 - - Latest News -
Repurposed diabetes drug could deliver gains for people living with major joint pain
April 27, 2025 - - Latest News